Geographic variation in attitudes regarding management of locally advanced pancreatic cancer.
Journal
Surgery open science
ISSN: 2589-8450
Titre abrégé: Surg Open Sci
Pays: United States
ID NLM: 101768812
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
15
07
2022
accepted:
30
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
6
9
2022
Statut:
epublish
Résumé
Recent literature suggests wide variations exist in the international management of locally advanced pancreatic cancer. This study sought to evaluate how geography contributes to variations in management of locally advanced pancreatic cancer. An electronic survey investigating preferences for the evaluation and management of locally advanced pancreatic cancer was distributed to an international cohort of pancreatic surgeons. Surgeons were classified according to geographic location of practice, and survey responses were compared across locations. A total of 153 eligible responses were received from 4 continents: North and South America (n = 94, 61.4%), Europe (n = 25, 16.3%), and Asia (n = 34, 22.2%). Preferences for the use and duration of neoadjuvant chemotherapy and radiotherapy varied widely. For example, participants in Asia commonly preferred 2 months of neoadjuvant chemotherapy (61.8%), whereas North and South American participants preferred 4 months (52.1%), and responses in Europe were mixed (P = .006). Participants in Asia were less likely to consider isolated liver or lung metastases contraindications to exploration and consequently had a greater propensity to consider exploration in a vignette of oligometastatic disease (56.7% vs North and South America: 25.6%, Europe: 43.5%; P = .007). In an international survey of pancreatic surgeons, attitudes regarding locally advanced pancreatic cancer and metastatic disease management varied widely across geographic locations. Better evidence is needed to define optimal management of locally advanced pancreatic cancer.
Sections du résumé
Background
UNASSIGNED
Recent literature suggests wide variations exist in the international management of locally advanced pancreatic cancer. This study sought to evaluate how geography contributes to variations in management of locally advanced pancreatic cancer.
Methods
UNASSIGNED
An electronic survey investigating preferences for the evaluation and management of locally advanced pancreatic cancer was distributed to an international cohort of pancreatic surgeons. Surgeons were classified according to geographic location of practice, and survey responses were compared across locations.
Results
UNASSIGNED
A total of 153 eligible responses were received from 4 continents: North and South America (n = 94, 61.4%), Europe (n = 25, 16.3%), and Asia (n = 34, 22.2%). Preferences for the use and duration of neoadjuvant chemotherapy and radiotherapy varied widely. For example, participants in Asia commonly preferred 2 months of neoadjuvant chemotherapy (61.8%), whereas North and South American participants preferred 4 months (52.1%), and responses in Europe were mixed (P = .006). Participants in Asia were less likely to consider isolated liver or lung metastases contraindications to exploration and consequently had a greater propensity to consider exploration in a vignette of oligometastatic disease (56.7% vs North and South America: 25.6%, Europe: 43.5%; P = .007).
Conclusion
UNASSIGNED
In an international survey of pancreatic surgeons, attitudes regarding locally advanced pancreatic cancer and metastatic disease management varied widely across geographic locations. Better evidence is needed to define optimal management of locally advanced pancreatic cancer.
Identifiants
pubmed: 36062077
doi: 10.1016/j.sopen.2022.07.007
pii: S2589-8450(22)00050-1
pmc: PMC9436766
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-105Informations de copyright
© 2022 The Authors.
Références
Ann Surg. 2019 Apr;269(4):733-740
pubmed: 29227344
Ann Surg. 2021 Feb 1;273(2):341-349
pubmed: 30946090
Pediatrics. 2014 Sep;134(3):563-70
pubmed: 25113303
Int J Cancer. 2018 Dec 15;143(12):3227-3239
pubmed: 29923613
Surgery. 2018 May;163(5):1090-1096
pubmed: 29395234
Eur J Surg Oncol. 2016 Oct;42(10):1533-9
pubmed: 27423449
Ann Surg. 2021 Jun 1;273(6):1173-1181
pubmed: 31449138
JAMA Ophthalmol. 2016 Mar;134(3):267-76
pubmed: 26720865
N Engl J Med. 1992 Apr 23;326(17):1097-101
pubmed: 1552910
Ann Surg Oncol. 2015 Jul;22(7):2179-94
pubmed: 25582739
Pancreatology. 2018 Oct;18(7):841-845
pubmed: 30075908
J Surg Oncol. 2013 Sep;108(4):236-41
pubmed: 23955427
JAMA. 1990 Feb 2;263(5):669-72
pubmed: 2404147
BMC Cancer. 2012 May 29;12:199
pubmed: 22642850
Chin J Cancer Res. 2015 Aug;27(4):358-67
pubmed: 26361405
Pediatrics. 2011 Jan;127(1):19-27
pubmed: 21172992
Ann Surg Oncol. 2017 Aug;24(8):2397-2403
pubmed: 28516291
Ann Surg. 2021 Mar 1;273(3):579-586
pubmed: 30946073
Dig Surg. 2018;35(1):70-76
pubmed: 28482348
Cancer Sci. 2011 Feb;102(2):478-83
pubmed: 21143703
Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a021535
pubmed: 26187874
Ann Surg. 2019 Aug;270(2):340-347
pubmed: 29596120
Eur J Surg Oncol. 2017 Feb;43(2):358-363
pubmed: 27856064
Cardiol Young. 2019 Sep;29(9):1127-1136
pubmed: 31414980
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S36-43
pubmed: 20620013
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
Ann Surg Oncol. 2021 Mar;28(3):1447-1456
pubmed: 33341916
Lancet. 2013 Sep 28;382(9898):1121-9
pubmed: 24075052
Arch Intern Med. 2010 Jul 26;170(14):1218-25
pubmed: 20660840
JAMA. 2010 Jul 14;304(2):180-6
pubmed: 20628131
Pancreas. 2020 Mar;49(3):326-335
pubmed: 32132516
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):438-447
pubmed: 33915091
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Int J Technol Assess Health Care. 1993 Spring;9(2):304-10
pubmed: 8458708
BMC Cancer. 2018 Mar 6;18(1):258
pubmed: 29510667
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457
pubmed: 33845462
BMC Cancer. 2011 Apr 19;11:145
pubmed: 21504577
Obesity (Silver Spring). 2019 Jan;27(1):161-165
pubmed: 30421849
Hepatobiliary Surg Nutr. 2019 Aug;8(4):345-360
pubmed: 31489304
Onco Targets Ther. 2011;4:193-201
pubmed: 22162925
J Clin Oncol. 2004 Sep 1;22(17):3466-74
pubmed: 15277535
Semin Radiat Oncol. 2017 Jan;27(1):3-10
pubmed: 27986209
Sci Rep. 2021 Feb 12;11(1):3774
pubmed: 33580139
Pancreatology. 2020 Sep;20(6):1131-1138
pubmed: 32739267
J Clin Oncol. 2005 Nov 1;23(31):7881-8
pubmed: 16204005
J Gastrointest Surg. 2021 Oct;25(10):2562-2571
pubmed: 34027578
HPB (Oxford). 2017 Mar;19(3):190-204
pubmed: 28215904
PLoS One. 2016 Dec 14;11(12):e0166762
pubmed: 27973617
JAMA. 2011 Mar 16;305(11):1113-8
pubmed: 21406648
Ann Surg Oncol. 2015 Jan;22(1):295-301
pubmed: 25037971
Ann Surg. 2016 Sep;264(3):457-63
pubmed: 27355262
Acta Obstet Gynecol Scand. 2012 Feb;91(2):220-5
pubmed: 22043840
BJOG. 2019 Nov;126(12):1456-1465
pubmed: 31449731
Br J Surg. 2019 May;106(6):756-764
pubmed: 30830974
N Engl J Med. 1992 Apr 23;326(17):1102-7
pubmed: 1552911
J Clin Oncol. 2014 Nov 10;32(32):3667-72
pubmed: 25287826
Prostate Cancer Prostatic Dis. 2015 Jun;18(2):149-54
pubmed: 25667110
Cancers (Basel). 2019 Jul 12;11(7):
pubmed: 31336859
Ir J Med Sci. 2006 Jul-Sep;175(3):32-9
pubmed: 17073245
Med Care. 2012 Mar;50(3):257-61
pubmed: 22329997
BMJ Open. 2019 Dec 8;9(12):e033452
pubmed: 31818843
J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605
pubmed: 31117041
BMC Cancer. 2019 Jul 9;19(1):675
pubmed: 31288786